Xiaoying Xie

Xiaoying Xie


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2025 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
MLMengna Liu
Mengna Liu
XJXi Jiang
Xi Jiang
YPYingqi Pi
Yingqi Pi
MCMingming Chen
Mingming Chen
XRXiuqin Ren
Xiuqin Ren
ZLZhaofan Luo
Zhaofan Luo
Hematological malignancy (HM) patients are at high risk of bloodstream infections (BSIs) due to chemotherapy-induced mucosal barrier injury (MBI), invasive procedures, and prolonged antimicrobial exposure. While conventional nosocomial infection paradigms emphasize catheter-related biofilms, emerging evidence highlights the role of disrupted oral/gut microbiomes in bacterial translocation. This study aimed to identify risk factors for bacteremia secondary to MBI following chemotherapy in patients with HM. A single-center, retrospective analysis of 72 HM patients, including 24 with mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI), 22 with non-MBI-LCBI, and 26 controls without BSIs, was conducted. Microbiology profiles, resistance patterns, and risk factors for BSIs were analyzed. All MBI-LCBI patients had significantly longer neutropenia duration than non-MBI-LCBI patients did (median 6.5 vs. 3.0 days, p = 0.013). Multivariate analysis identified MBI as an independent risk factor for BSIs (OR = 11.467, 95% CI1.287–102.170). Prolonged hospitalization (> 30 days) was associated with BSI occurrence (OR = 6.758, 95% CI 1.102–41.440) and neutropenia duration (OR = 1.112, 95% CI 1.014–1.220). Significant differences in pathogen distribution were observed between groups: Escherichia coli, Klebsiella pneumoniae, and viridans group streptococci predominated in the MBI-LCBI group, whereas Pseudomonas aeruginosa and Staphylococcus spp. were common in the non-MBI-LCBI group. Carbapenem resistance remained below 20% for key gram-negative pathogens. MBI is an independent risk factor for BSI in HM patients, highlighting the need for targeted mucosal protection strategies. MBI-LCBI pathogens primarily originate from the gut/oral flora, and are distinct from catheter-related infections. Carbapenems are recommended for empirical therapy, yet resistance surveillance remains essential.

1 December 2025 in Infection and Drug Resistance
Verified
Journal Article
Open access
MLMengna Liu
Mengna Liu
XJXi Jiang
Xi Jiang
YPYingqi Pi
Yingqi Pi
XRXiuqin Ren
Xiuqin Ren
MCMingming Chen
Mingming Chen
XXXiaoying Xie
Xiaoying Xie
Background: Agrobacterium radiobacter (A. radiobacter) is a gram-negative environmental bacterium primarily found in soil and plants. While it exhibits low virulence, it can act as an opportunistic pathogen in immunocompromised hosts. Its variable antibiotic resistance patterns pose challenges in clinical management. In this context, we reported a case of catheter-related bloodstream infection (CRBSI) caused by A. radiobacter and reviewed its clinical features, diagnostic challenges, and treatment strategies. Case Presentation: A 70-year-old male with stage IIIA gastric adenocarcinoma and a chemotherapy-associated central venous catheter (CVC) presented with fever and elevated procalcitonin (3.02 ng/mL). Blood cultures from CVC and periphery grew A. radiobacter. Empirical piperacillin/tazobactam transiently improved symptoms, but recurrent fever prompted CVC removal on day 10 of hospitalization, leading to rapid resolution of fever, normalization of procalcitonin, and negative follow-up blood cultures. Conclusion: This case highlights the critical role of catheter removal and susceptibility-guided antibiotic therapy for A. radiobacter infections in immunocompromised patients, addressing biofilm challenges and informing antimicrobial stewardship. Collaborative research integrating microbiology, genomics, and clinical data is essential to refine treatment algorithms and improve outcomes in immunocompromised hosts.